Cost-Effectiveness Analysis of Bezlotoxumab Added to Standard of Care Versus Standard of Care Alone for the Prevention of Recurrent Clostridium difficile Infection in High-Risk Patients in Spain

Authors: Salavert M, Cobo J, Pascual Á, Aragón B, Maratia S, Jiang Y, Aceituno S, Grau S

Journal: Advances in Therapy

Year: 2018

Reference: Adv Ther. 2018 Oct 16. doi: 10.1007/s12325-018-0813-y. [Epub ahead of print]

Outside URL

Subscribe to Outcomes´10

Name *

E-mail *

Todos los campos marcados con un * son obligatorios

Responsible for the data: Outcomes'10, s.l.u., Purpose: Sending commercial communications. Legitimation: Art. 6.1 Consent of the interested party. Recipient: No data is transferred unless expressly authorised. You may exercise your rights on data protection (access, rectification, opposition, deletion, automated decisions, limitation of treatment, portability) by email at dpo@outcomes10.com. Data will be retained for the time necessary to fulfill its purpose and derived responsibilities by current regulations and the deadlines in the applicable regulations on archives and documentation. In any case, you can request the protection of the Spanish Data Protection Agency through its website www.aepd.es/. In addition, you can consult more information on the privacy policy

I have read and accepted the privacy policy